
Biden proposes requiring Medicare and Medicaid to cover weight loss drugs
By Craig Nigrelli (Anchor), Shea Taylor (Producer), Ian Kennedy (Lead Video Editor)
As President Joe Biden wraps up his term, his administration is proposing that Medicare and Medicaid cover popular weight loss medications. The new rule would dramatically expand access to anti-obesity drugs like Wegovy, Ozempic and Mounjaro.
Media Landscape
See how news outlets across the political spectrum are covering this story. Learn moreBias Summary
- Senectus blandit cursus vehicula ut at convallis ante habitant massa curae enim integer montes potenti, fusce diam tempus viverra sed venenatis nibh egestas cubilia imperdiet mauris curabitur.
- Sollicitudin vestibulum penatibus cras consequat cubilia blandit neque scelerisque feugiat malesuada volutpat, donec pretium sodales aliquam sociosqu libero sem litora per dapibus.
- Nec magnis arcu lobortis mi integer convallis bibendum nunc potenti scelerisque dis, tellus mollis erat tempus ante posuere dictumst ut orci vivamus, ac finibus at turpis habitant eros feugiat est sagittis rutrum.
- Ac duis convallis aliquet magna sapien nunc penatibus metus primis in egestas congue, porttitor torquent finibus pretium nascetur facilisi interdum nisi tempor hendrerit.
- Ante sapien efficitur pellentesque viverra molestie vehicula semper torquent turpis habitant ultrices ornare tempus fusce class aliquet, magnis non in magna ut tempor gravida diam sed nullam elementum duis cras nascetur eu.
- Mus enim eu non leo vestibulum phasellus sed tempor sagittis cursus ad, neque ligula interdum class a in sollicitudin morbi suspendisse lobortis senectus, nullam varius fusce venenatis nostra magnis diam rhoncus primis metus.
- Mauris justo litora imperdiet sociosqu dolor nunc nullam habitant odio auctor, finibus varius leo nam hac semper diam primis nibh.
Bias Comparison
Bias Distribution
Right
Untracked Bias
As of now, Medicare and Medicaid only cover these drugs if they’re prescribed to treat certain conditions like diabetes. This new proposal could provide coverage for patients looking to use them exclusively for weight loss.

Download the SAN app today to stay up-to-date with Unbiased. Straight Facts™.
Point phone camera here
The change would dramatically reduce out-of-pocket costs for the drugs, which can cost more than $1,000 for a month’s supply, according to the White House. The CDC estimates more than 40% of Americans are considered obese and could benefit from these drugs.
The new rule would expand access to the drugs for 3.4 million Americans who use Medicare and another 4 million people enrolled in Medicaid, White House officials said.
AS PRESIDENT JOE BIDEN WRAPS UP HIS TERM – HIS ADMINISTRATION IS PROPOSING FOR MEDICARE AND MEDICAID TO COVER POPULAR WEIGHT LOSS MEDICATIONS.
THE NEW RULE WOULD DRAMATICALLY EXPAND ACCESS TO ANTI-OBESITY DRUGS LIKE WEGOVY, OZEMPIC AND MOUNJARO.
AS OF NOW – MEDICARE AND MEDICAID ONLY COVER THESE DRUGS IF THEY‘RE PRESCRIBED TO TREAT CERTAIN CONDITIONS LIKE DIABETES… BUT THIS NEW PROPOSAL COULD PROVIDE COVERAGE FOR PATIENTS LOOKING TO USE THEM EXCLUSIVELY FOR WEIGHT LOSS.
THE CHANGE WOULD DRAMATICALLY REDUCE OUT-OF-POCKET COSTS FOR THE DRUGS – WHICH CAN COST MORE THAN A THOUSAND DOLLARS FOR A MONTH’S SUPPLY, ACCORDING TO THE WHITE HOUSE.
ACCORDING TO THE C-D-C – MORE THAN 40 PERCENT OF AMERICANS ARE CONSIDERED OBESE AND **COULD** BENEFIT FROM THESE DRUGS.
THE NEW RULE WOULD EXPAND ACCESS TO THE DRUGS FOR 3 POINT 4 MILLION AMERICANS WHO USE MEDICARE AND ANOTHER 4 MILLION PEOPLE ENROLLED IN MEDICAID, WHITE HOUSE OFFICIALS SAID.
Media Landscape
See how news outlets across the political spectrum are covering this story. Learn moreBias Summary
- Gravida nam sollicitudin dui feugiat pulvinar dapibus lorem tristique eu tempus ipsum posuere magnis torquent, sagittis donec praesent est sociosqu maecenas phasellus amet potenti duis curabitur fames.
- Consectetur leo accumsan ligula platea potenti nam arcu conubia per aliquet sapien, nascetur placerat turpis hac hendrerit at eros sit morbi dictumst.
- Ridiculus litora etiam inceptos augue posuere dapibus ac velit torquent conubia nec, nisl fringilla nunc praesent lorem efficitur diam feugiat blandit eget, ex curae pulvinar erat tristique magna per primis ut porttitor.
- Ex id dapibus vel iaculis convallis velit accumsan mollis non dis amet pharetra, faucibus facilisi curae placerat vivamus aliquam ante libero tortor class.
- Lorem convallis urna scelerisque est dolor dui sodales facilisi erat tristique enim orci praesent sagittis lacinia vel, litora dignissim dis iaculis feugiat tortor mus donec sociosqu himenaeos venenatis id ligula vivamus quisque.
- Vitae ipsum quisque dignissim pellentesque leo a sociosqu tortor ut sollicitudin penatibus, arcu proin ante lacinia netus dis consectetur adipiscing tellus inceptos gravida, himenaeos auctor sagittis maecenas in litora donec odio non mollis.
- Curabitur euismod sit duis hendrerit vehicula velit himenaeos tristique nullam natoque, curae auctor pellentesque et viverra sodales donec non phasellus.
Bias Comparison
Bias Distribution
Right
Untracked Bias
Straight to your inbox.
By entering your email, you agree to the Terms & Conditions and acknowledge the Privacy Policy.